Rachelle Jacques Net Worth

The estimated Net Worth of Rachelle Suzanne Jacques is at least $1.43 Million dollars as of 13 June 2024. Ms. Jacques owns over 2,221 units of Corbus Pharmaceuticals Inc stock worth over $759,446 and over the last 6 years she sold CRBP stock worth over $62,270. In addition, she makes $606,338 as Independent Director at Corbus Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Jacques CRBP stock SEC Form 4 insiders trading

Rachelle has made over 3 trades of the Corbus Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 2,221 units of CRBP stock worth $11,416 on 13 June 2024.

The largest trade she's ever made was selling 2,301 units of Corbus Pharmaceuticals Inc stock on 13 June 2023 worth over $43,167. On average, Rachelle trades about 273 units every 26 days since 2019. As of 13 June 2024 she still owns at least 14,408 units of Corbus Pharmaceuticals Inc stock.

You can see the complete history of Ms. Jacques stock trades at the bottom of the page.

Rachelle Jacques biography

Rachelle Suzanne Jacques serves as Independent Director of the Company. Ms. Jacques has served as a director since April 2019. Ms. Jacques has served as the Chief Executive Officer of Enzyvant Therapeutics, Inc., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), focused on developing therapies for patients with rare diseases, since February 2019. Previously, beginning in 2017, she served as the Senior Vice President and Global Complement Franchise Head at Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), where she was responsible for global franchise strategy development and execution. From 2016 to 2017, Ms. Jacques was Vice President of U.S Hematology Marketing at Shire plc, which acquired Baxalta Inc. (“Baxalta”) in 2016. Prior to this role, from 2015 to 2016, Ms. Jacques served as Vice President of Business Operations at Baxalta after its spinoff from Baxter International Inc. (NYSE: BAX) (“Baxter”) in 2015. From 2013 to 2015, Ms. Jacques served in leadership positions, including Vice President of Finance, US BioScience Business, at Baxter. Prior to joining Baxter, from 1995 to 2013, Ms. Jacques served in various roles of increasing responsibility at Dow Corning Corporation, including U.S. and international operational management roles. Ms. Jacques received her B.A. degree in business administration from Alma College. Ms. Jacques was selected as a director due to her multinational business leadership and commercialization experience, particularly in the biotechnology industry.

What is the salary of Rachelle Jacques?

As the Independent Director of Corbus Pharmaceuticals Inc, the total compensation of Rachelle Jacques at Corbus Pharmaceuticals Inc is $606,338. There are 4 executives at Corbus Pharmaceuticals Inc getting paid more, with Yuval Cohen having the highest compensation of $4,001,510.

How old is Rachelle Jacques?

Rachelle Jacques is 49, she's been the Independent Director of Corbus Pharmaceuticals Inc since 2019. There are 10 older and 1 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.

What's Rachelle Jacques's mailing address?

Rachelle's mailing address filed with the SEC is C/O UNIQURE N. V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.

Insiders trading at Corbus Pharmaceuticals Inc

Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor..., and Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.

What does Corbus Pharmaceuticals Inc do?

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.

Complete history of Ms. Jacques stock trades at Akari Therapeutics Plc, Corbus Pharmaceuticals Inc, uniQure N.V, and Viela Bio

Corbus Pharmaceuticals Inc executives and stock owners

Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Yuval Cohen,
  Chief Executive Officer, Director
• Barbara White,
  Chief Medical Officer 
• Sean Moran,
  Chief Financial Officer
• Dr. Yuval Cohen,
  CEO & Director
• Rachelle Jacques,
  Independent Director
• Sean F. Moran CPA, M.B.A., CPA, MBA,
  Chief Financial Officer
• Alan Holmer,
  Independent Chairman of the Board
• Avery Catlin,
  Independent Director
• John Jenkins,
  Independent Director
• Ted Jenkins,
  Senior Director, Investor Relations and Communications
• Peter Salzmann,
  Independent Director
• Craig Millian,
  Chief Commercial Officer
• Scott Constantine,
  Sr. Director & Head of Clinical Operations
• Christina Bertsch,
  Head of HR
• Lindsey Smith,
  Head of Corp. Communications & Patient Advocacy
• Dr. Rachael Brake Ph.D.,
  Chief Scientific Officer
• Craig Stuart Millian M.B.A.,
  Chief Operating Officer.
• David P Hochman,
  Director
• Mark Tepper,
  President and CSO
• Renu Gupta,
  Director
• George Golumbeski,
  Director
• Asset Management, Lp Cormor...,
  
• Anne Altmeyer,
  
• Yong Ben,
  
• Paris Panayiotopoulos,
  Director
• Asset Management, Lp Chen B...,
  
• Dominic Smethurst,
  Chief Medical Officer
• Sumner Burstein,
  10% owner
• Robert Paul Discordia,
  Chief Operating Officer
• Rachael Louise Brake,
  Chief Scientific Officer
• Winston Kung,